echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The new drug treatment plan for Hepatitis C was approved for sale.

    The new drug treatment plan for Hepatitis C was approved for sale.

    • Last Update: 2020-08-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Guide: The all-oral hepatitis C treatment is composed of Ravidawe (Shinlilai) in conjunction with Danoriv (Gonovi).
    Co., Ltd. announced today that its all-oral hepatitis C treatment program has been approved for listing by the State Drug Administration of China.
    's all-oral hepatitis C treatment (RDV/DNV treatment) is made up of Ravidawe (Xinlilai) in conjunction with Danorive (Gonove).
    The results of Phase II/III clinical trials completed in China showed that, after 12 weeks of treatment, the RDV/DNV treatment regimen had a cure rate of 99% in patients with gene type 1 non-cirrhosis (SVR12), and 100% of patients with NS5A drug resistance mutations at baseline shaded.
    Ravidawe and Danoriwe have been supported by the national 13th Five-Year New Drug Creation science and technology projects.
    2014, Clarisse acquired an exclusive interest in Ravidawe in Greater China from Presidio.
    Presidio is a clinical pharmaceutical company.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.